WO2006084018A3 - Methods for determining responsiveness to cancer therapy - Google Patents

Methods for determining responsiveness to cancer therapy Download PDF

Info

Publication number
WO2006084018A3
WO2006084018A3 PCT/US2006/003660 US2006003660W WO2006084018A3 WO 2006084018 A3 WO2006084018 A3 WO 2006084018A3 US 2006003660 W US2006003660 W US 2006003660W WO 2006084018 A3 WO2006084018 A3 WO 2006084018A3
Authority
WO
WIPO (PCT)
Prior art keywords
dimers
respond
treatment
acting agent
her2
Prior art date
Application number
PCT/US2006/003660
Other languages
French (fr)
Other versions
WO2006084018A2 (en
Inventor
Mengxiang Tang
Liching Cao
Rajiv Dua
Ali Mukherjee
Herjit Pannu
Jagrup Pannu
Yining Shi
Yuping Tan
Sharat Singh
Colombe Chappey
Original Assignee
Monogram Biosciences Inc
Mengxiang Tang
Liching Cao
Rajiv Dua
Ali Mukherjee
Herjit Pannu
Jagrup Pannu
Yining Shi
Yuping Tan
Sharat Singh
Colombe Chappey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monogram Biosciences Inc, Mengxiang Tang, Liching Cao, Rajiv Dua, Ali Mukherjee, Herjit Pannu, Jagrup Pannu, Yining Shi, Yuping Tan, Sharat Singh, Colombe Chappey filed Critical Monogram Biosciences Inc
Publication of WO2006084018A2 publication Critical patent/WO2006084018A2/en
Publication of WO2006084018A3 publication Critical patent/WO2006084018A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Abstract

In certain aspects, the present invention provides methods and compositions for determining whether a cancer cells is likely to respond to treatment with a Her 1 -acting agent. In one aspect, the invention provides a method for determining whether a cancer cell is likely to respond to treatment with a Her 1 -acting agent, comprising detecting on the cancer cell at least about 600 Her 1 -Her 1 dimers, wherein the presence of the at least about 600 Her 1 -Her 1 dimers indicates that the cancer is likely to respond to treatment with the Her 1 -acting agent. In another aspect, the invention provides a method for determining whether a cancer cell is likely to respond to treatment with a Her 1 -acting agent, comprising detecting on a cell of the cancer at least about 600 Her 1 -Her 1 dimers, at least about 1000 Herl-Her2 dimers, and fewer than about 1000 Her2-Her3 dimers, wherein the presence of the at least about 600 Her 1 -Her 1 dimers, the at least about 1000 Herl-Her2 dimers, and the fewer than about 1000 Her2-Her3 dimers indicates that the cancer cell is likely to respond to treatment with the Her 1 -acting agent. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.
PCT/US2006/003660 2005-02-02 2006-02-01 Methods for determining responsiveness to cancer therapy WO2006084018A2 (en)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US64954905P 2005-02-02 2005-02-02
US60/649,549 2005-02-02
US67835705P 2005-05-05 2005-05-05
US60/678,357 2005-05-05
US68092305P 2005-05-14 2005-05-14
US60/680,923 2005-05-14
US71105605P 2005-08-23 2005-08-23
US60/711,056 2005-08-23
US71201905P 2005-08-25 2005-08-25
US60/712,019 2005-08-25
US72886505P 2005-10-19 2005-10-19
US60/728,865 2005-10-19

Publications (2)

Publication Number Publication Date
WO2006084018A2 WO2006084018A2 (en) 2006-08-10
WO2006084018A3 true WO2006084018A3 (en) 2006-09-21

Family

ID=36777898

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/003660 WO2006084018A2 (en) 2005-02-02 2006-02-01 Methods for determining responsiveness to cancer therapy

Country Status (1)

Country Link
WO (1) WO2006084018A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44437E1 (en) 2003-04-01 2013-08-13 Monogram Biosciences, Inc. Methods for detecting receptor complexes comprising PI3K
US9085622B2 (en) 2010-09-03 2015-07-21 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins
US9110066B2 (en) 2009-01-15 2015-08-18 Laboratory Corporation Of America Holdings HER-3 antibodies and methods of use

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10416162B2 (en) 2007-12-20 2019-09-17 Monogram Biosciences, Inc. Her2 diagnostic methods
WO2010065568A2 (en) 2008-12-01 2010-06-10 Laboratory Corporation Of America Holdings METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
EP3403095B1 (en) 2016-03-15 2019-08-07 Laboratory Corporation of America Holdings Methods of assessing protein interactions between cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AMANN J. ET AL: "Aberrant Epidermal Growth Factor Receptor Signaling and Enhanced Sensitivity to EGFR Inhibitors in Lung Cancer", CANCER RESEARCH, vol. 65, no. 1, 1 January 2005 (2005-01-01), pages 226 - 235, XP002397276 *
NAKAMURA H. ET AL: "Correlation Between Encoded Protein Overexpressing and Copy Number of the HER2 Gene with Survival in Non-Small Cell Lung Cancer", INTERNATIONAL JOURNAL OF CANCER, vol. 103, 2003, pages 61 - 66, XP003005359 *
NORMANNO N. ET AL: "Epidermal growth factor receptor (EGFR) signaling in cancer", GENE, vol. 366, 2006, pages 2 - 16, XP005282074 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44437E1 (en) 2003-04-01 2013-08-13 Monogram Biosciences, Inc. Methods for detecting receptor complexes comprising PI3K
US9110066B2 (en) 2009-01-15 2015-08-18 Laboratory Corporation Of America Holdings HER-3 antibodies and methods of use
US9085622B2 (en) 2010-09-03 2015-07-21 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins

Also Published As

Publication number Publication date
WO2006084018A2 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
WO2006044748A3 (en) RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
WO2007041502A3 (en) Methods for determining responsiveness to cancer therapy
WO2006137941A3 (en) Methods and compositions involving mirna and mirna inhibitor molecules
HK1116836A1 (en) Multicomponent nucleic acid enzymes and methods for their use
WO2007035684A3 (en) Method for quantitative detection of short rna molecules
WO2010045318A3 (en) Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
WO2004034988A3 (en) Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
WO2006084018A3 (en) Methods for determining responsiveness to cancer therapy
WO2004078938A3 (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2005084109A3 (en) Cancer specific gene mh15
WO2009005809A3 (en) Compositions and methods for treating and diagnosing cancer
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
WO2008061213A3 (en) Genetic variations associated with tumors
WO2006078289A3 (en) Bio-barcode based detection of target analytes
WO2008008515A3 (en) Methods and compositions for detecting rare cells from a biological sample
WO2006031800A3 (en) Reverse transfection of cell arrays
WO2003062462A3 (en) Method for isolating nucleic acids and protein from a single sample
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
WO2011070441A3 (en) Categorization of dna samples
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
WO2008088860A3 (en) Polymorphisms in the egfr pathway as markers for cancer treatment
WO2009051201A1 (en) Anti-bst2 antibody
WO2007058968A3 (en) Gene expression profiles and methods of use
WO2006053315A3 (en) Methods and compositions for treating cellular proliferative diseases
WO2009027978A8 (en) NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06720138

Country of ref document: EP

Kind code of ref document: A2